Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Itero Biopharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

The biosimilars business isn't necessarily a logical niche for a small start-up company. The industry's many attendant challenges-clinical, manufacturing, and regulatory-are more the domain of the established generics companies, big biotechs, and more recently Big Pharmas, which have the capital and infrastructure to handle them. Try telling that to Itero Biopharmaceuticals, which plans to develop follow-on therapeutic proteins and antibodies en route to creating its own biologics pipeline. In order to compete in this multibillion-dollar market, Itero intends to forge and leverage strategic partnerships in far-flung corners of the world.

You may also be interested in...

Start-Up Previews (02/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Building the Next-Generation of GPCR-Targeting Drugs," features profiles of Catena Pharmaceuticals, Dimerix Bioscience, Heptares Therapeutics and Trevena. Plus these Start-Ups Across Health Care: Carmat, Glycan Biosciences, Itero and MaRVis Technologies.

Biosimilars: The Time Has Come

Biosimilars' time has come--in Europe, at least. The European regulators asserted during a workshop in Paris at the beginning of December that biosimilars guidelines will be finalized before mid-2006. This will open up a market which could be worth $8 billion within five years in the EU, according to the European Generic Association (EGA).

Biosimilars: EMEA Wants Approvals

European regulators’ guidelines on biosimilars show that they are serious about quickly approving cheaper follow-on biologics. The hurdles may come thereafter.


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts